「mr」の検索結果
57件：26～30件目を表示
-
Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) discov...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
family V member 1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announce that “Avarept® Ophthalmic suspension ...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
ase through TRPV1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announce that “Avarept® Ophthalmic Suspension ...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
family V member 1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announce that “Avarept® Ophthalmic suspension ...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf